Nasdaq:US$18.12 (-0.52) | HKEX:HK$28.75 (-0.90) | AIM:£2.93 (-0.03)
新聞中心及演示文稿
上一篇文章   |   下一篇文章
演示文稿, 科學出版物 | 2013-04-06

AACR 2013: Phase I study of safety and pharmacokinetics of fruquintinib, a selective inhibitor of VEGF receptor -1, -2, and -3 tyrosine kinases in patients with advanced solid tumors